Klarer Kauf - 500 Beiträge pro Seite
eröffnet am 27.10.03 06:28:09 von
neuester Beitrag 22.11.03 10:07:58 von
neuester Beitrag 22.11.03 10:07:58 von
Beiträge: 18
ID: 789.665
ID: 789.665
Aufrufe heute: 0
Gesamt: 899
Gesamt: 899
Aktive User: 0
Top-Diskussionen
| Titel | letzter Beitrag | Aufrufe |
|---|---|---|
| vor 51 Minuten | 5840 | |
| vor 52 Minuten | 5699 | |
| vor 43 Minuten | 3611 | |
| heute 14:48 | 3164 | |
| vor 51 Minuten | 2615 | |
| heute 16:44 | 2401 | |
| heute 15:55 | 1832 | |
| vor 42 Minuten | 1700 |
Meistdiskutierte Wertpapiere
| Platz | vorher | Wertpapier | Kurs | Perf. % | Anzahl | ||
|---|---|---|---|---|---|---|---|
| 1. | 1. | 17.738,02 | -0,21 | 149 | |||
| 2. | 2. | 150,38 | -3,26 | 136 | |||
| 3. | 4. | 6,8700 | -7,16 | 72 | |||
| 4. | 3. | 2.385,88 | +1,06 | 58 | |||
| 5. | 5. | 6,7220 | +1,94 | 55 | |||
| 6. | Neu! | 6,6540 | +8,09 | 44 | |||
| 7. | Neu! | 12,310 | -0,28 | 44 | |||
| 8. | 29. | 22,390 | +4,43 | 40 |
Feedback
Too Gourmet, Inc. kooperiert mit deutscher Biotechklinik.
Handelbar in New York unter TGOU oder Berlin unter WKN 661768. Freitag bereits +63% nach folgender News:
Too Gourmet, Inc. Executes Letter of Intent With German Medical Laboratory
Wednesday, October 22, 2003 18:07 ET
IRVINE, Calif., Oct 22, 2003 (BUSINESS WIRE) -- Too Gourmet, Inc. (OTCBB:TGOU) is pleased to announce that it has entered into a non-binding Letter of Intent to acquire the medical business assets and related intellectual property of a medical laboratory doing business as the Internationale Fachklinik (" lab" ) located in Schwerin, Germany from Drs. H. Reimann and A. Reimann. The transaction is subject to due diligence review, negotiations and drafting of the definitive purchase agreement, which includes representations and warranties standard for a transaction of this nature and magnitude. Terms of the proposed transaction have not been disclosed.
Under the direction of Dr. H. Reimann, Professor at Humboldt University in Berlin, Germany, PhD. in Biochemistry and PhD. in Medicine, the lab specializes in the research, analysis, and in vitro diagnosis of live biopsy tissue samples for allergic, immunological, and environmentally related disorders. In order to improve the quality of test results, Dr. Reimann developed and patented a unique device known as a " Tabox" , which enables the precise analysis of the effects of allergens and toxins on the human body in an in vitro environment.
Human tissue samples are taken from patients using skin punches or biopsy tongs. The samples are then kept alive, or incubated, for an extended period of time in a Tabox, a mobile device, which simulates the body`s functions. The Taboxes are then transported by courier to the lab for analysis and testing of the contained tissue samples. Practitioners, attendants and physicians at outpatient clinics then use the results and findings as a form of diagnosis prior to the treatment of their patients. As a result, during the diagnosis process, these individuals are not exposed to additional toxins and allergens, which could aggravate existing conditions of the patient.
Currently, the lab operates a total of 28 inter-clinic Tabox systems as proprietary devices, which are available to practitioners, clinics and other medical customers on a lease basis. The lessees are charged a user fee for each tissue sample processed at the lab. During calendar year 2003, the lab has reported gross revenues of approximately $1.2 million and pre-tax earnings of approximately 30% of sales. According to Dr. Reimann, 28 Tabox systems operated at capacity could generate gross revenues of up to $2.8 million annually. Dr. Reimann anticipates the production and use of up to 100 Tabox systems by its medical customers by the end of the third quarter 2004. In addition, new labs and research facilities are projected to be established in Zurich, Switzerland and Berlin, Germany during 2005.
The occurrence and effects of allergic disorders are on the rise worldwide. Increasingly, individuals suffer allergic reactions to pollen, mold spores, animal fur, and house dust mites. Allergic reactions may also occur as a result of exposure to sun, insecticides, pesticides or certain types of foods. In Germany, approximately 20 % of the population or 16.5 million people suffer from some type of allergic disorder of which allergic rhino conjunctivitis is the most common and widespread in children.
The Private Securities Litigation Reform Act of 1995 provides a " safe harbor" for forward-looking statements. Certain information included in this press release contains statements that are forward-looking, such as statements related to the future anticipated direction of the industry, plans for future expansion, various business development activities, planned capital expenditures, future funding sources, anticipated sales growth and potential contracts. Such forward-looking information involves important risks and uncertainties that could significantly affect anticipated results in the future and, accordingly, such results may differ from those expressed in any forward-looking statements made by, or on behalf of Too Gourmet, Inc. These risks and uncertainties include, but are not limited to, those relating to development and expansion activities, dependence on existing management, financing activities, and domestic and global economic conditions.
SOURCE: Too Gourmet, Inc.
Handelbar in New York unter TGOU oder Berlin unter WKN 661768. Freitag bereits +63% nach folgender News:
Too Gourmet, Inc. Executes Letter of Intent With German Medical Laboratory
Wednesday, October 22, 2003 18:07 ET
IRVINE, Calif., Oct 22, 2003 (BUSINESS WIRE) -- Too Gourmet, Inc. (OTCBB:TGOU) is pleased to announce that it has entered into a non-binding Letter of Intent to acquire the medical business assets and related intellectual property of a medical laboratory doing business as the Internationale Fachklinik (" lab" ) located in Schwerin, Germany from Drs. H. Reimann and A. Reimann. The transaction is subject to due diligence review, negotiations and drafting of the definitive purchase agreement, which includes representations and warranties standard for a transaction of this nature and magnitude. Terms of the proposed transaction have not been disclosed.
Under the direction of Dr. H. Reimann, Professor at Humboldt University in Berlin, Germany, PhD. in Biochemistry and PhD. in Medicine, the lab specializes in the research, analysis, and in vitro diagnosis of live biopsy tissue samples for allergic, immunological, and environmentally related disorders. In order to improve the quality of test results, Dr. Reimann developed and patented a unique device known as a " Tabox" , which enables the precise analysis of the effects of allergens and toxins on the human body in an in vitro environment.
Human tissue samples are taken from patients using skin punches or biopsy tongs. The samples are then kept alive, or incubated, for an extended period of time in a Tabox, a mobile device, which simulates the body`s functions. The Taboxes are then transported by courier to the lab for analysis and testing of the contained tissue samples. Practitioners, attendants and physicians at outpatient clinics then use the results and findings as a form of diagnosis prior to the treatment of their patients. As a result, during the diagnosis process, these individuals are not exposed to additional toxins and allergens, which could aggravate existing conditions of the patient.
Currently, the lab operates a total of 28 inter-clinic Tabox systems as proprietary devices, which are available to practitioners, clinics and other medical customers on a lease basis. The lessees are charged a user fee for each tissue sample processed at the lab. During calendar year 2003, the lab has reported gross revenues of approximately $1.2 million and pre-tax earnings of approximately 30% of sales. According to Dr. Reimann, 28 Tabox systems operated at capacity could generate gross revenues of up to $2.8 million annually. Dr. Reimann anticipates the production and use of up to 100 Tabox systems by its medical customers by the end of the third quarter 2004. In addition, new labs and research facilities are projected to be established in Zurich, Switzerland and Berlin, Germany during 2005.
The occurrence and effects of allergic disorders are on the rise worldwide. Increasingly, individuals suffer allergic reactions to pollen, mold spores, animal fur, and house dust mites. Allergic reactions may also occur as a result of exposure to sun, insecticides, pesticides or certain types of foods. In Germany, approximately 20 % of the population or 16.5 million people suffer from some type of allergic disorder of which allergic rhino conjunctivitis is the most common and widespread in children.
The Private Securities Litigation Reform Act of 1995 provides a " safe harbor" for forward-looking statements. Certain information included in this press release contains statements that are forward-looking, such as statements related to the future anticipated direction of the industry, plans for future expansion, various business development activities, planned capital expenditures, future funding sources, anticipated sales growth and potential contracts. Such forward-looking information involves important risks and uncertainties that could significantly affect anticipated results in the future and, accordingly, such results may differ from those expressed in any forward-looking statements made by, or on behalf of Too Gourmet, Inc. These risks and uncertainties include, but are not limited to, those relating to development and expansion activities, dependence on existing management, financing activities, and domestic and global economic conditions.
SOURCE: Too Gourmet, Inc.
da sind 727170 / 630300 / 523560 interessanter !!!!
Die kommen von 3 € und wurden dazwischen kaum gehandelt.
Das gibt ein Feuerwerk.
Das gibt ein Feuerwerk.
Liegt auch an der brachgelegenen Shell ohne Business in den letzten Monaten und Jahren. Das könnte was werden mit dem Kursfeuerwerk. 
Hat jemand von Euch Realtime Berlin,ich kann nichts sehen?
Trading Spotlight
Es werden gerade mal 300 Stück zu 0,81 € in Berlin angeboten. Denke mal, die Nachricht hat sich noch nicht rumgesprochen, dass es bei TGOU jetzt interessant werden könnte...
Die sind ja gestern wieder gestiegen in Amiland.
In den USA 1,31 in Berlin 0,70€ ,wie geht das?
Rennt die bis 5 € ?
Jetzt bei 1,69 € in Berlin und 2,10$ in USA
Und es geht jeden Tag weiter.
Und es geht jeden Tag weiter.
Und Sie steigt und steigt und steigt.
wow..was für ein chart!
ride the train!!!
ride the train!!!
Der Chart sieht wirklich einmalig aus und es ist kein Ende abzusehen.
Berlin ist derzeit 30% billiger als OTC.
mal sehen wie lange noch.
Schließlich wollen die ja eine Deutsche Firma kaufen.
Berlin ist derzeit 30% billiger als OTC.
mal sehen wie lange noch.
Schließlich wollen die ja eine Deutsche Firma kaufen.
Und was glaubst Du, wie lange wird dieser Trend noch anhalten? Weiss jemand mehr über das Unternehmen?
News!!!!
Too Gourmet, Inc. Completes Acquisition of Assets of German Medical Laboratory
Wednesday, November 05, 2003 09:01 ET
IRVINE, Calif., Nov 5, 2003 (BUSINESS WIRE) -- Too Gourmet, Inc. (OTCBB:TGOU) is pleased to announce that it has completed the acquisition of the medical business assets and related intellectual property of a medical laboratory and service provider, doing business as the Internationale Fachklinik ("lab") located in Schwerin, Germany from Prof. Dr. Hans-Jurgen Reimann and Dr. Antje Reimann.
In connection with the acquisitions, Prof. Reimann will be appointed to serve as the company`s Chairman of the Board and as its Chief Executive Officer. Dr. A. Reimann will be appointed to the Board of Directors of the company. The international law firm of Bryan Cave LLP will continue its engagement with the company as its corporate securities counsel.
Under the direction of Prof. Reimann, Professor at University of Rostock and at Humboldt University in Berlin, Germany, PhD. in Biochemistry and PhD. in Medicine, the lab specializes in the research, analysis, and in vitro diagnosis of live biopsy tissue samples for allergic, immunological, and environmentally related disorders. In order to improve the quality of test results, Prof. Reimann developed and patented a unique device known as a "Tabox", which enables the precise analysis of the effects of allergens and toxins on the human body in an in vitro environment.
Currently, the lab operates a total of twenty-eight inter-clinic Tabox systems as proprietary devices, which are available to practitioners, clinics, and other medical clients on a lease-only basis. The lab charges its lessees a user fee for each tissue sample processed at the lab. According to Prof. Reimann, the operation of twenty-eight Tabox systems at capacity could generate revenues of up to $2.8 million annually. Prof. Reimann anticipates the production and use of up to one hundred Tabox systems by its clients by the end of the third quarter of 2004. During the 2003 calendar year, the lab has reported revenues of approximately $1.2 million and pre-tax profits of approximately 30% of sales.
The company is in preliminary negotiations to acquire all of the outstanding stock of a German medical devices, equipment, and apparatus manufacturer that currently produces the Tabox for the lab. "The purchase of the equipment manufacturer could be a strategic acquisition, ensuring timely production and commercial "roll out" of the proprietary Tabox systems and expansion of the lab`s services in Western Europe," said Prof. Reimann. "In addition, the manufacturer`s fiscal performance could contribute significantly to the company`s revenues and earnings in 2004. Furthermore, the acquisition of the manufacturer could help to diversify the company`s products and services portfolio into other potentially profitable niche markets." The manufacturer anticipates revenues of approximately $7.5 million and pre-tax profits of approximately $2.0 million in the current calendar year 2003.
The Private Securities Litigation Reform Act of 1995 provides a "safe harbor" for forward-looking statements. Certain information included in this press release contains statements that are forward-looking, such as statements related to the future anticipated direction of the industry, plans for future expansion, various business development activities, planned capital expenditures, future funding sources, anticipated sales growth and potential contracts. Such forward-looking information involves important risks and uncertainties that could significantly affect anticipated results in the future and, accordingly, such results may differ from those expressed in any forward-looking statements made by, or on behalf of Too Gourmet, Inc. These risks and uncertainties include, but are not limited to, those relating to development and expansion activities, dependence on existing management, financing activities, and domestic and global economic conditions.
SOURCE: Too Gourmet, Inc.
Too Gourmet, Inc. Completes Acquisition of Assets of German Medical Laboratory
Wednesday, November 05, 2003 09:01 ET
IRVINE, Calif., Nov 5, 2003 (BUSINESS WIRE) -- Too Gourmet, Inc. (OTCBB:TGOU) is pleased to announce that it has completed the acquisition of the medical business assets and related intellectual property of a medical laboratory and service provider, doing business as the Internationale Fachklinik ("lab") located in Schwerin, Germany from Prof. Dr. Hans-Jurgen Reimann and Dr. Antje Reimann.
In connection with the acquisitions, Prof. Reimann will be appointed to serve as the company`s Chairman of the Board and as its Chief Executive Officer. Dr. A. Reimann will be appointed to the Board of Directors of the company. The international law firm of Bryan Cave LLP will continue its engagement with the company as its corporate securities counsel.
Under the direction of Prof. Reimann, Professor at University of Rostock and at Humboldt University in Berlin, Germany, PhD. in Biochemistry and PhD. in Medicine, the lab specializes in the research, analysis, and in vitro diagnosis of live biopsy tissue samples for allergic, immunological, and environmentally related disorders. In order to improve the quality of test results, Prof. Reimann developed and patented a unique device known as a "Tabox", which enables the precise analysis of the effects of allergens and toxins on the human body in an in vitro environment.
Currently, the lab operates a total of twenty-eight inter-clinic Tabox systems as proprietary devices, which are available to practitioners, clinics, and other medical clients on a lease-only basis. The lab charges its lessees a user fee for each tissue sample processed at the lab. According to Prof. Reimann, the operation of twenty-eight Tabox systems at capacity could generate revenues of up to $2.8 million annually. Prof. Reimann anticipates the production and use of up to one hundred Tabox systems by its clients by the end of the third quarter of 2004. During the 2003 calendar year, the lab has reported revenues of approximately $1.2 million and pre-tax profits of approximately 30% of sales.
The company is in preliminary negotiations to acquire all of the outstanding stock of a German medical devices, equipment, and apparatus manufacturer that currently produces the Tabox for the lab. "The purchase of the equipment manufacturer could be a strategic acquisition, ensuring timely production and commercial "roll out" of the proprietary Tabox systems and expansion of the lab`s services in Western Europe," said Prof. Reimann. "In addition, the manufacturer`s fiscal performance could contribute significantly to the company`s revenues and earnings in 2004. Furthermore, the acquisition of the manufacturer could help to diversify the company`s products and services portfolio into other potentially profitable niche markets." The manufacturer anticipates revenues of approximately $7.5 million and pre-tax profits of approximately $2.0 million in the current calendar year 2003.
The Private Securities Litigation Reform Act of 1995 provides a "safe harbor" for forward-looking statements. Certain information included in this press release contains statements that are forward-looking, such as statements related to the future anticipated direction of the industry, plans for future expansion, various business development activities, planned capital expenditures, future funding sources, anticipated sales growth and potential contracts. Such forward-looking information involves important risks and uncertainties that could significantly affect anticipated results in the future and, accordingly, such results may differ from those expressed in any forward-looking statements made by, or on behalf of Too Gourmet, Inc. These risks and uncertainties include, but are not limited to, those relating to development and expansion activities, dependence on existing management, financing activities, and domestic and global economic conditions.
SOURCE: Too Gourmet, Inc.
52W HIGH: New 52-Wk High for TGOU @ $2.500 up2.04%
Friday , November 07, 2003 12:16 ET
This is the 1st 52 WEEK HIGH alert for TGOU in the past 7 calendar days.
The share price for Too Gourmet Incorporated (OTCBB: TGOU) reached a new 52-week high today, trading at $2.500, up $0.050 (2.04%) from its previous close of $2.450.
The Company`s previous 52-week high of $2.450 was set yesterday on November 06, 2003.
One year ago, the Company`s shares closed at $1.960. The price has climbed more than 27 percent since then.
At the time of this alert, the stock had traded 3,400 shares via 3 trades, 70.64% below it`s 20day average of 11,579 shares.
This new 52-week high currently puts the stock:
149.50% above its 20day Moving Average of $1.002
350.29% above its 50day Moving Average of $0.555
496.66% above its 100day Moving Average of $0.419
The Company last released news on November 05, 2003:
"Too Gourmet, Inc. Completes Acquisition of Assets of German Medical Laboratory
Friday , November 07, 2003 12:16 ET
This is the 1st 52 WEEK HIGH alert for TGOU in the past 7 calendar days.
The share price for Too Gourmet Incorporated (OTCBB: TGOU) reached a new 52-week high today, trading at $2.500, up $0.050 (2.04%) from its previous close of $2.450.
The Company`s previous 52-week high of $2.450 was set yesterday on November 06, 2003.
One year ago, the Company`s shares closed at $1.960. The price has climbed more than 27 percent since then.
At the time of this alert, the stock had traded 3,400 shares via 3 trades, 70.64% below it`s 20day average of 11,579 shares.
This new 52-week high currently puts the stock:
149.50% above its 20day Moving Average of $1.002
350.29% above its 50day Moving Average of $0.555
496.66% above its 100day Moving Average of $0.419
The Company last released news on November 05, 2003:
"Too Gourmet, Inc. Completes Acquisition of Assets of German Medical Laboratory
steigt und steigt
52W HIGH: New 52-Wk High for TGOU @ $2.940 up3.52%
Tuesday , November 18, 2003 12:36 ET
This is the 3rd 52 WEEK HIGH alert for TGOU in the past 7 calendar days.
The share price for Too Gourmet Incorporated (OTCBB: TGOU) reached a new 52-week high today, trading at $2.940, up $0.100 (3.52%) from its previous close of $2.840.
The Company`s previous 52-week high of $2.850 was set yesterday on November 17, 2003.
One year ago, the Company`s shares closed at $1.250. The price has climbed more than 135 percent since then.
At the time of this alert, the stock had traded 3,500 shares via 3 trades, 82.62% below it`s 20day average of 20,139 shares.
This new 52-week high currently puts the stock:
62.03% above its 20day Moving Average of $1.815
235.08% above its 50day Moving Average of $0.877
408.65% above its 100day Moving Average of $0.578
The Company last released news on November 05, 2003:
"Too Gourmet, Inc. Completes Acquisition of Assets of German Medical Laboratory"
52W HIGH: New 52-Wk High for TGOU @ $2.940 up3.52%
Tuesday , November 18, 2003 12:36 ET
This is the 3rd 52 WEEK HIGH alert for TGOU in the past 7 calendar days.
The share price for Too Gourmet Incorporated (OTCBB: TGOU) reached a new 52-week high today, trading at $2.940, up $0.100 (3.52%) from its previous close of $2.840.
The Company`s previous 52-week high of $2.850 was set yesterday on November 17, 2003.
One year ago, the Company`s shares closed at $1.250. The price has climbed more than 135 percent since then.
At the time of this alert, the stock had traded 3,500 shares via 3 trades, 82.62% below it`s 20day average of 20,139 shares.
This new 52-week high currently puts the stock:
62.03% above its 20day Moving Average of $1.815
235.08% above its 50day Moving Average of $0.877
408.65% above its 100day Moving Average of $0.578
The Company last released news on November 05, 2003:
"Too Gourmet, Inc. Completes Acquisition of Assets of German Medical Laboratory"
Hi,
kann mir jemand sagen warum kein aktueller kurs angezeigt wird?
gruß und im voraus vielen dank
vegas
kann mir jemand sagen warum kein aktueller kurs angezeigt wird?
gruß und im voraus vielen dank
vegas
DurchsuchenBeitrag zu dieser Diskussion schreiben
Zu dieser Diskussion können keine Beiträge mehr verfasst werden, da der letzte Beitrag vor mehr als zwei Jahren verfasst wurde und die Diskussion daraufhin archiviert wurde.
Bitte wenden Sie sich an feedback@wallstreet-online.de und erfragen Sie die Reaktivierung der Diskussion oder starten Sie eine neue Diskussion.
Meistdiskutiert
| Wertpapier | Beiträge | |
|---|---|---|
| 151 | ||
| 137 | ||
| 67 | ||
| 57 | ||
| 57 | ||
| 41 | ||
| 40 | ||
| 36 | ||
| 35 | ||
| 35 |
| Wertpapier | Beiträge | |
|---|---|---|
| 31 | ||
| 29 | ||
| 27 | ||
| 27 | ||
| 24 | ||
| 23 | ||
| 22 | ||
| 20 | ||
| 20 | ||
| 19 |
